#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2730	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2602	307.8	0	.	n	.	0	C451T	SNP	451	451	C	927	927	T	387	T,C,A	345,3,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2730	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2602	307.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1660	1660	C	377	C	347	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4242	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4051	311.2	0	.	n	.	0	T695C	SNP	695	695	T	1200	1200	C	317	C,A	279,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4242	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4051	311.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2476	2476	C	400	C,T,G	369,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4242	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4051	311.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3102	3102	T	387	T,C,A	261,81,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4242	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4051	311.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2550	2550	A	426	A	385	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	640	folP	855	855	100.0	folP.l6.c17.ctg.1	1957	96.9	1	SNP	p	R229S	1	.	.	685	687	AGC	1265	1267	AGC	137;136;136	A;G;C	127;125;118	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1070	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3856	82.1	1	SNP	p	S91F	1	.	.	271	273	TTC	857	859	TTC	102;102;102	T;T;C	88;88;92	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1070	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3856	82.1	1	SNP	p	G95N	0	.	.	283	285	GGC	869	871	GGC	103;103;103	G;G;C	91;89;88	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1070	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3856	82.1	1	SNP	p	D95G	1	.	.	283	285	GGC	869	871	GGC	103;103;103	G;G;C	91;89;88	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	560	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1772	93.5	1	SNP	p	G45D	0	.	.	133	135	GGC	678	680	GGC	145;145;147	G;G;C	133;136;133	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	370	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1604	68.7	0	.	n	.	0	A197.	DEL	197	197	A	846	846	A	134	A	124	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1082	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3559	90.2	1	SNP	p	D86N	0	.	.	256	258	GAC	836	838	GAC	111;111;112	G;A,G;C	95;95,1;96	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1082	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3559	90.2	1	SNP	p	R87I	0	.	.	259	261	CGT	839	841	CGT	111;111;111	C,A;G;T	98,1;98;96	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1082	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3559	90.2	1	SNP	p	S87R	1	.	.	259	261	CGT	839	841	CGT	111;111;111	C,A;G;T	98,1;98;96	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1082	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3559	90.2	1	SNP	p	R87W	0	.	.	259	261	CGT	839	841	CGT	111;111;111	C,A;G;T	98,1;98;96	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1082	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3559	90.2	1	SNP	p	S88P	0	.	.	262	264	TCC	842	844	TCC	111;110;111	T;C;C	97;97;95	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1020	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3194	94.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1929	1931	GGC	128;127;127	G;G;C	124;121;116	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	772	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2841	80.6	1	SNP	p	A311V	0	.	.	931	933	GCC	1477	1479	GCC	88;88;88	G;C;C,A	76;77;80,1	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	772	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2841	80.6	1	SNP	p	I312M	1	.	.	934	936	ATG	1480	1482	ATG	88;88;89	A;T;G	79;78;78	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	772	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2841	80.6	1	SNP	p	T316P	0	.	.	946	948	ACC	1492	1494	ACC	90;90;90	A;C;C	80;77;78	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	772	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2841	80.6	1	SNP	p	V316T	1	.	.	946	948	ACC	1492	1494	ACC	90;90;90	A;C;C	80;77;78	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	772	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2841	80.6	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1993	1995	ACC	134;134;134	A;C;C	114;116;118	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	772	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2841	80.6	1	SNP	p	A501P	0	.	.	1501	1503	GCG	2047	2049	GCG	145;144;143	G;C;G	125;118;125	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	772	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2841	80.6	1	SNP	p	A501V	0	.	.	1501	1503	GCG	2047	2049	GCG	145;144;143	G;C;G	125;118;125	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	772	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2841	80.6	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2170	2172	GGT	122;121;121	G;G;T	110;110;113	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	772	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2841	80.6	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2179	2181	AGC	124;124;124	A;G;C	111;112;112	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	772	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2841	80.6	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2197	2199	CCG	125;125;125	C,G;C;G	101,1;109;108	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1004	ponA	2397	2397	100.0	ponA.l6.c30.ctg.1	3535	84.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1847	1849	CCG	104;105;105	C,T;C;G	87,1;91;94	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	606	porA	1146	1146	99.91	porA.l6.c4.ctg.1	2271	79.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	840	840	C	105	C	94	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	566	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	2080	80.5	0	.	p	.	0	I45V	NONSYN	133	135	ATT	719	721	GTT	127;127;127	G;T;T	120;116;119	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	566	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	2080	80.5	0	.	p	.	0	F131L	NONSYN	391	393	TTT	977	979	CTT	117;117;116	C;T;T	102;100;100	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	566	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	2080	80.5	0	.	p	.	0	G321S	NONSYN	961	963	GGC	1547	1549	AGC	105;105;105	A;G;C,A,T	96;92;87,1,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	566	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	2080	80.5	1	SNP	p	G120K	1	.	.	358	360	AAG	944	946	AAG	118;118;117	A;A;G	104;104;105	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	566	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	2080	80.5	1	SNP	p	N121D	0	.	.	361	363	AAC	947	949	AAC	117;118;117	A;A;C	103;104;105	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	566	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	2080	80.5	1	SNP	p	A121N	1	.	.	361	363	AAC	947	949	AAC	117;118;117	A;A;C	103;104;105	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1300	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5272	73.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	220	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1467	44.7	1	SNP	p	V57M	1	.	.	169	171	ATG	759	761	ATG	81;82;82	A;T;G	75;73;74	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
